Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Slides:

Advertisements

Similar presentations

Oncotype DX® Breast Cancer Assay Clinical Data Review

Advertisements

Xeloda X-panding options in the adjuvant treatment of breast cancer

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

Triple-Negative Breast Cancer

Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.

Giuliano Pre-SSO mins ASCO Z mins

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

TATFACFAC Combined NEO pCRRDTotalpCRRDTotalpCRRDTotalpCRRDTotal ER ER Total

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

What is Cancer? How it occurs and cell cycle regulation.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.

Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.

Ct value Log concentration miR-375 miR-221 Supplementary Figure S1.

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv TRAB/2FTRAB/2O GFs B M.W. None=0

Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Table S1. Characteristics of breast tumor and normal breast tissue samples. Relevant characteristics of breast tumor and normal breast tissue samples analyzed.

Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS > CTPX > SBX6, >

ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.

Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.

Table S1. Demographics and Patient Pathology Results Total number of patients40 Male (%)29 (72%) Female (%)11 (28%) Age Range47 – 86 Median Age70 Organ.

Prognostic value of ER, PR, and HER2 breast cancer biomarkers and AJCC’s TNM staging system on overall survival of Caucasian females with breast cancer.

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Supplementary table 1 miR-506 expression and clinocopathological factors FactorsTotal number miR-506 low expressionmiR-506 high expression P-value (n =

Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.

Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Should liver metastases of breast cancer be biopsied to improve treatment choice? M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio,

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

Table S1. CD44 expression and clinicopathologic characteristics Cases (n=54) CD44 protein expression P value* Negativ e WeakStrong (n=8)(n=23) Age

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

SpecimenCTCTissue MarkerAntibodySourceAntibodySource ER monoclonal murine ER Janssen Diagnostics, LLC monoclonal murine, clone 1D5, 1:50, high pH.

Insert Footer or Copyright Information Here

Number of brain metastasis

Training Set Clinicopathological parameters of the training set

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Supplementary Table 1. (A) S100β Validation set (n=76 ER-positive and ER-negative patients). (B) S100β Validation set (n=59 ER-positive patients). Association.

سرطان الثدي Breast Cancer

Preparing for Checkpoint Inhibitors in Breast Cancer

Table S1: Characteristics of the cancer patients

Supplementary Fig S1, Zembutsu H et al.

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Ki-67 expression is determined by the cell-cycle stage.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Presentation transcript:

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median age (years)56 (26-86) Tumor category T149 T237 T314 Chemotherapy, no (%) Yes55 No45 Radiation Therapy, no (%) Yes56 No44 Stage, no (%) I45 II44 III11 ER status, no (%) Positive56 Negative44 PR status, no (%) Positive55 Negative45 HER-2 status, no (%) Positive33 Negative67 TNBC, no (%) Positive27 Negative73

Supplementary Table 2: Interacting proteins of LMW-E(T1) identified from RePCA screen

Supplementary Table 3: Doubling time (hrs.) of 76NE6 TDCs+KD ACLY Scr.shRNAshACLY #1shACLY #2 Parental EL T

Supplementary Table 4: ACLY inhibition delays tumor formation Cyclin E Expression shRNA sequence # of tumors 3 weeks # of tumors 12 weeks Vector Scr.shRNA100% (5/5) shACLY #1100% (5/5) shACLY#2100% (5/5) EL Scr.shRNA100% (5/5) shACLY #1100% (5/5) shACLY#2100% (5/5) LMW-E(T1) Scr.shRNA100% (5/5) shACLY #180% (4/5)100% (5/5) shACLY#240% (2/5) LMW-E(T2) Scr.shRNA100% (5/5) shACLY #10% (0/5)100% (5/5) shACLY#220% (1/5)40% (2/5)

ConditionIntensityPercentage (%) Adipophilin H-score* Ki-67 (%) (Mean) SEMLMWE Vector Scr positive Vector shACLY# negative Vector shACLY# negative EL Scr positive EL shACLY# negative EL shACLY# positive T1 Scr positive T1 shACLY# negative T2 shACLY# negative T2 Scr positive T2 shACLY# negative T2 shACLY# negative Supplementary Table 5: Adipophilin, Ki-67 and LMW-E immuno- expression in xenograft tumors *H score: Summary of intensity and percentage score; 0-3: low; 4-7 high

Supplementary Table 6 : Adipophilin scoring system ScoreIntensityPercentage 0negative0 1weakly positive<5% 2moderately positive6-25% 3strong positive26-75% 4strong positive>75%